Drug Database
AM

amiodarone (Nexterone / PM101 / amiodarone, Prism)

✓ Approved

Baxter International, Inc. · SCN5A · 小分子

什么是 amiodarone?

amiodarone 是一种小分子,由Baxter International, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Nexterone, PM101, amiodarone, Prism
公司Baxter International, Inc.
药物类别小分子
分子靶点SCN5A
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

amiodarone 作用于 1 个分子靶点:

SCN5Asodium voltage-gated channel alpha subunit 5 (CMD1E, SSS1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

amiodarone 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersVentricular fibrillation✓ Approved
Cardiac disordersVentricular tachycardia✓ Approved

相关研究文献

PubMedAnalytical chemistry2026-11-18

A HClO/miR-214 AND-Gated DNA Triangular Prism Nanoprobe for Stage-Resolved Imaging of Macrophage-to-Foam Cell Transformation in Atherosclerosis.

Zhang Fangmei F, Jiang Xiaotong X, Tian Xuemei X, Qiu Yue Y et al.

Macrophage-to-foam cell transformation is a hallmark of early atherosclerosis. Accurate molecular imaging of this process remains analytically challenging due to insufficient cell-type selectivity and complex microenvironmental interference. To address these challenges, a dual-input AND-gated DNA triangular prism (TPCM) nanoprobe is developed. Fluorescence turn-on of this probe requires the simultaneous recognition of endogenous HClO and miR-214, which are concurrently elevated during foam-cell formation. Through spatial confinement, the rigid triangular prism scaffold accelerates DNAzyme catalytic kinetics by 2.52-fold compared to unconfined systems. In ox-LDL-stimulated RAW 264.7 macrophages, TPCM produces dose-dependent fluorescence responses that effectively distinguish distinct stages of foam-cell progression. These signal variations closely correlate with progressive lipid accumulation and the elevation of both HClO and miR-214, which are further corroborated by the expression of foam-cell markers MMP-9 and ITGβ1. The strict logic-gating mechanism significantly minimizes false-positive signals in non-target endothelial cells and LPS-induced inflammatory macrophage models. Beyond profiling foam-cell stages, TPCM successfully tracks the suppression of intracellular targets in response to pharmacological inhibitors (e.g., 4-aminobenzoic acid hydrazide and Calphostin C). This logic-gated platform can serve as a promising analytical tool for stage-resolved imaging of macrophage-to-foam cell transformation and evaluating related anti-atherosclerotic therapeutics.

PMID 43046416
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Cosmetic Bont-A-Induced Transient Esotropia: A Case Expanding the Clinical Spectrum of Lateral Rectus Involvement.

Akyol Tunahan T, Un Emine Seker ES, Parca Osman O

To present a rare case of transient esodeviation and binocular diplopia caused by unintended medial rectus involvement following periocular botulinum toxin type A (BoNT-A) injection performed in a non-medical setting. A 39-year-old female with no systemic disease presented with a 1-day history of painless horizontal binocular diplopia. Five days before symptom onset, she had received a cosmetic BoNT-A injection into the glabellar, forehead, and lateral canthal regions at a non-medical beauty center. Ophthalmic examination revealed a visual acuity of 0.0 logMAR bilaterally, normal anterior and posterior segment findings, and a 10-prism-diopter esodeviation in primary gaze. Extraocular motility demonstrated full ductions without restrictive patterns. Worth four-dot testing showed right-eye suppression, and stereopsis was markedly reduced. Cranial nerve and neurological examinations were normal. Orbital-cranial CT and MRI were unremarkable. The clinical picture was consistent with unintended diffusion of the toxin, leading to transient medial rectus overaction. The patient was managed conservatively with prism correction. Prism strength was gradually reduced over follow-up (8 PD → 6 PD → 2 PD), and prisms were discontinued by month four. Full resolution of diplopia occurred at month six, consistent with the expected timeframe of neuromuscular recovery after BoNT-A exposure. Medial rectus involvement following cosmetic BoNT-A injection is extremely rare but may result in symptomatic diplopia and functional visual impairment. This case emphasizes that botulinum toxin injections must be performed exclusively by trained medical professionals with appropriate anatomical knowledge. Early recognition of cosmetic injection-related strabismus is essential to avoid unnecessary neurological workup and to ensure timely conservative management.

PMID 43047067
阅读全文 →
PubMedCardiology in review2026-11-18

Vernakalant Versus Other Antiarrhythmic Drugs for Pharmacological Cardioversion of Recent-Onset Atrial Fibrillation: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.

Elawfi Bashaer B, Elazab Ahmed A, Thobaiti Faisal Talal Al FTA, Alnefaie Reema Sultan RS et al.

Vernakalant is an atrial-selective antiarrhythmic drug for the rapid conversion of recent-onset atrial fibrillation, but its effectiveness relative to alternative drugs remains uncertain. This systematic review and meta-analysis included studies comparing intravenous vernakalant with another antiarrhythmic drug in adults with recent-onset atrial fibrillation. PubMed, Embase, Scopus, and Web of Science were searched through March 2026. The primary outcome was conversion to sinus rhythm; secondary outcomes were time to conversion, electrical cardioversion, and adverse events. Random-effects models, trial sequential analysis, and GRADE were used. Nine studies (3 randomized, 1 quasi-randomized, and 5 observational; 1788 patients or episodes) compared vernakalant with amiodarone, ibutilide, flecainide, procainamide, or propafenone. Conversion occurred in 69.0% of patients receiving vernakalant and 53.0% of those receiving a comparator (odds ratio [OR], 2.52; 95% confidence interval [CI], 1.51-4.21; I2 = 72%). Heterogeneity was explained by the amiodarone comparisons (OR, 18.14; interaction P < 0.001); against the other comparators, the OR was 1.77 (95% CI, 1.41-2.22; I2 = 0%). Vernakalant shortened time to conversion among responders (mean difference, -19.3 minutes; 95% CI, -24.2 to -14.4) and reduced electrical cardioversion (OR, 0.50; 95% CI, 0.34-0.73), without a significant difference in adverse events (OR, 0.78; 95% CI, 0.57-1.08). The cumulative Z-curve crossed the trial sequential monitoring boundary, but the certainty of evidence was low for all outcomes.

PMID 43046311
阅读全文 →
PubMedTherapeutic advances in hematology2026-11-18

Real-life venous thromboembolism risk scores in multiple myeloma receiving daratumumab, lenalidomide, and dexamethasone.

Liberatore Carmine C, Candeloro Matteo M, Fioritoni Francesca F, Potere Nicola N et al.

Treatment with daratumumab and lenalidomide has improved survival in patients with multiple myeloma (MM), however the risk of venous thromboembolism (VTE) is high. Data on the accuracy of VTE risk scores in MM receiving daratumumab are limited. To assess (i) the prognostic accuracy of available VTE risk scores (IMPEDE-VTE, SAVED, PRISM, and EHR-CAT scores) in non-transplant-eligible MM (NTE-MM) and relapsed/refractory MM (RRMM) consecutively treated with daratumumab, lenalidomide and dexamethasone (Dara-Rd); and (ii) the feasibility and safety of guideline-recommended thromboprophylaxis with low molecular weight heparin for 6 months followed by aspirin (LMWH-ASA). Single-center, retrospective, cohort study. All consecutive MM patients treated with Dara-Rd and concomitant LMWH-ASA thromboprophylaxis between July, 2018 and September, 2023 were evaluated through chart review. Kaplan-Meier method and Concordance-Index (C-index) were used to estimate risk scores' prognostic accuracy. 95 patients (median age 74 years) were included (n= 47 NTE-MM, and n= 48 RRMM). At 12 months from Dara-Rd initiation, 10 (10.4%) patients developed VTE; 4 (4.2%) had bleeding complications, and 2 (2.1%) patients died. Six VTE events (6.2%) occurred within first 6 months from Dara-Rd initiation while on LMWH prophylaxis, whereas 2 VTE (2%) developed in two patients receiving aspirin. The accuracy of IMPEDE-VTE, SAVED, PRISM and EHR-CAT scores was generally poor, with C-Index values ranging from 0.43 (95% confidence intervals [95%CI] 0.30 to 0.56) to 0.53 (95%CI: 0.38 to 0.68). LMWH-ASA prophylaxis was completed by 89.5% of the cohort. In this real-life cohort of MM patients treated with Dara-Rd and guideline-recommended antithrombotic prophylaxis, currently available VTE risk scores demonstrated moderate to poor prognostic accuracy. LMWH-ASA prophylaxis was feasible but associated with residual VTE risk.

PMID 43048015
阅读全文 →
PubMedAnalytical chemistry2026-11-18

APE1-Responsive Adaptive DNA Nanomachines for Prolonged Intracellular Bioanalysis and Sustained Gene Silencing.

Li Xiao-Qiong XQ, Zhu Ye Y, Ye Zhi-Fan ZF, Wang Jianhao J et al.

Rapid cellular clearance severely restricts the effective analytical and functional windows of intracellular probes. Herein, we developed an endogenous enzyme-driven adaptive DNA nanomachine (TRZL) that synchronizes target recognition with in situ morphological transformation to overcome premature cellular clearance for prolonged intracellular theranostics. Specifically, a spatially confined hybridization chain reaction (HCR) circuit and an apurinic/apyrimidinic endonuclease 1 (APE1)-responsive module, which initially locks a DNAzyme, are integrated onto a rigid DNA prism framework. In tumor cells, APE1 recognition triggers the HCR circuit accompanied by fluorescence recovery, enabling sensitive APE1 detection with an ultralow limit of detection (LOD) of 9.60 × 10-4 U/mL. Concurrently, the continuous extension of the HCR polymers drives an in situ hydrodynamic size expansion from 37 nm monomers into 479 nm 3-dimensional networks. The resulting steric hindrance effectively mitigates rapid cellular clearance, successfully extending the signal retention window by maintaining 85.34% of the APE1-triggered signal over 24 h. Furthermore, benefiting from this aggregation-driven retention, the synchronously released DNAzyme can continuously cleave survivin mRNA to achieve sustained protein downregulation, thereby extending the functional window. Ultimately, this programmable size-adaptive strategy provides a highly versatile theranostic platform for precise bioanalysis and long-acting intervention.

PMID 43046359
阅读全文 →
PubMedCureus2026-11-18

Blocking the Sympathetic Storm: Adjunctive Left Stellate Ganglion Block for Refractory Ventricular Tachycardia After Inferolateral Myocardial Infarction.

Goyal Mohit M, Razdan Shriya S, Ghosh Soumik S, Prajapati Rajpal R et al.

Electrical storm following myocardial infarction (MI) can be difficult to control when antiarrhythmic drugs and cardioversion fail. We describe a 53-year-old man with hypertension and previously undiagnosed diabetes who presented with an inferolateral ST-segment elevation MI caused by total occlusion of the proximal left circumflex artery, which was treated with primary percutaneous coronary intervention and drug-eluting stent placement. He then developed marked leukocytosis with a systemic inflammatory response and acute kidney injury (peak creatinine, 4.03 mg/dL), which resolved with empirical antibiotic therapy and supportive renal care. On day 6, he experienced recurrent syncope associated with sustained monomorphic ventricular tachycardia (VT) that persisted despite intravenous amiodarone and lidocaine, electrolyte correction, and repeated cardioversion, necessitating sedation and mechanical ventilation. Repeat coronary angiography demonstrated a patent stent. VT ceased following an ultrasound-guided left stellate ganglion block (SGB) using 1% lidocaine and dexamethasone, which resulted in Horner syndrome. Antiarrhythmic therapy was continued, and the patient was extubated within 24 hours. Speckle-tracking echocardiography demonstrated severely reduced lateral and anterior strain (global longitudinal strain, -12.0%). A patent stent in the culprit vessel and sustained monomorphic arrhythmia made a scar-related substrate the leading consideration. The close temporal association between the block and cessation of VT suggests that sympathetic blockade may have contributed to arrhythmia control, although the continuation of antiarrhythmic therapy precludes firm causal conclusions. Left SGB may serve as a rapid bridge to definitive treatment in patients with refractory electrical storm.

PMID 43048759
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多amiodarone